{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:12Z","timestamp":1790487072136,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>microRNAs (miRs) dysregulation have emerged as a crucial step in tumorigenesis, being related with cancer development, progression and response to treatment. In chronic myeloid leukaemia (CML), the resistance to tyrosine kinase inhibitors (TKI) is responsible for treatment failure and could be linked to changes in miRs expression. This work aimed to correlate the expression levels of 3 miRs, miR-21, miR-26b and miR-451, with response to TKI treatment in CML patients. miR-451 levels at diagnosis were significantly higher in patients with optimal response after 6 and 12 months of therapy. Conversely, patients without optimal response had highest levels of miR-21. miR-21 and miR-451 appear to be good biomarkers of response, able to predict optimal TKI responders (p\u2009&lt;\u20090.05). Using the combined profile of both miRs, we create a predictive model of optimal response after one year of treatment. This study highlights the role of miR-21 and miR-451 expression levels at diagnosis in predicting which patients achieve the optimal response.<\/jats:p>","DOI":"10.1038\/s41598-019-46132-9","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T14:24:03Z","timestamp":1562250243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["MicroRNA signature refine response prediction in CML"],"prefix":"10.1038","volume":"9","author":[{"given":"Raquel","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-4802","authenticated-orcid":false,"given":"Ana Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Lu\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-2310","authenticated-orcid":false,"given":"Andr\u00e9 B.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Freitas-Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Oliveiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio M.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bela","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"46132_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher, A. & Slack, F. J. Oncomirs \u2014 microRNAs with a role in cancer. Nature Reviews Cancer 6, 259, https:\/\/doi.org\/10.1038\/nrc1840 (2006).","journal-title":"Nature Reviews Cancer"},{"key":"46132_CR2","first-page":"172","volume":"10","author":"S Alizadeh","year":"2016","unstructured":"Alizadeh, S., Azizi, S. G., Soleimani, M., Farshi, Y. & Kashani Khatib, Z. The Role of MicroRNAs in Myeloproliferative Neoplasia. International Journal of Hematology-Oncology and Stem Cell Research 10, 172\u2013185 (2016).","journal-title":"International Journal of Hematology-Oncology and Stem Cell Research"},{"key":"46132_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ceb.2009.03.002","volume":"21","author":"M Negrini","year":"2009","unstructured":"Negrini, M., Nicoloso, M. S. & Calin, G. A. MicroRNAs and cancer\u2014new paradigms in molecular oncology. Current Opinion in Cell Biology 21, 470\u2013479, https:\/\/doi.org\/10.1016\/j.ceb.2009.03.002 (2009).","journal-title":"Current Opinion in Cell Biology"},{"key":"46132_CR4","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/j.1742-4658.2011.08087.x","volume":"278","author":"A Ichimura","year":"2011","unstructured":"Ichimura, A., Ruike, Y., Terasawa, K. & Tsujimoto, G. miRNAs and regulation of cell signaling. The FEBS Journal 278, 1610\u20131618, https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08087.x (2011).","journal-title":"The FEBS Journal"},{"key":"46132_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3322\/caac.21244","volume":"64","author":"I Berindan-Neagoe","year":"2014","unstructured":"Berindan-Neagoe, I., Monroig, P. D. C., Pasculli, B. & Calin, G. A. MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA: A Cancer Journal for Clinicians 64, 311\u2013336, https:\/\/doi.org\/10.3322\/caac.21244 (2014).","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"46132_CR6","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1080\/10428194.2016.1243676","volume":"58","author":"Z Litwi\u0144ska","year":"2017","unstructured":"Litwi\u0144ska, Z. & Machali\u0144ski, B. miRNAs in chronic myeloid leukemia: small molecules, essential function. Leukemia & Lymphoma 58, 1297\u20131305, https:\/\/doi.org\/10.1080\/10428194.2016.1243676 (2017).","journal-title":"Leukemia & Lymphoma"},{"key":"46132_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.blre.2016.11.003","volume":"31","author":"Q Fernandes","year":"2017","unstructured":"Fernandes, Q. MicroRNA: Defining a new niche in Leukemia. Blood Reviews 31, 129\u2013138, https:\/\/doi.org\/10.1016\/j.blre.2016.11.003 (2017).","journal-title":"Blood Reviews"},{"key":"46132_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley, J. F. Chronic myeloid leukaemia. The Lancet 385, 1447\u20131459, https:\/\/doi.org\/10.1016\/S0140-6736(13)62120-0 (2015).","journal-title":"The Lancet"},{"key":"46132_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","volume":"274","author":"G Volpe","year":"2009","unstructured":"Volpe, G., Panuzzo, C., Ulisciani, S. & Cilloni, D. Imatinib resistance in CML. Cancer Letters 274, 1\u20139, https:\/\/doi.org\/10.1016\/j.canlet.2008.06.003 (2009).","journal-title":"Cancer Letters"},{"key":"46132_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.apsb.2016.09.002","volume":"7","author":"X An","year":"2017","unstructured":"An, X., Sarmiento, C., Tan, T. & Zhu, H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharmaceutica Sinica B 7, 38\u201351, https:\/\/doi.org\/10.1016\/j.apsb.2016.09.002 (2017).","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"46132_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.12364","volume":"162","author":"JEA Gordon","year":"2013","unstructured":"Gordon, J. E. A., Wong, J. J. L. & Rasko, J. E. J. MicroRNAs in myeloid malignancies. British Journal of Haematology 162, 162\u2013176, https:\/\/doi.org\/10.1111\/bjh.12364 (2013).","journal-title":"British Journal of Haematology"},{"key":"46132_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0518-2","volume":"15","author":"C-H Yeh","year":"2016","unstructured":"Yeh, C.-H., Moles, R. & Nicot, C. Clinical significance of microRNAs in chronic and acute human leukemia. Molecular Cancer 15, 37, https:\/\/doi.org\/10.1186\/s12943-016-0518-2 (2016).","journal-title":"Molecular Cancer"},{"key":"46132_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/br.2016.747","volume":"5","author":"Y-H Feng","year":"2016","unstructured":"Feng, Y.-H. & Tsao, C.-J. Emerging role of microRNA-21 in cancer. Biomedical Reports 5, 395\u2013402, https:\/\/doi.org\/10.3892\/br.2016.747 (2016).","journal-title":"Biomedical Reports"},{"key":"46132_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.febslet.2010.12.027","volume":"585","author":"H Bai","year":"2010","unstructured":"Bai, H., Xu, R., Cao, Z., Wei, D. & Wang, C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Letters 585, 402\u2013408, https:\/\/doi.org\/10.1016\/j.febslet.2010.12.027 (2010).","journal-title":"FEBS Letters"},{"key":"46132_CR15","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/onc.2012.190","volume":"32","author":"T Palumbo","year":"2012","unstructured":"Palumbo, T. et al. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN\u2013AKT pathway. Oncogene 32, 1651, https:\/\/doi.org\/10.1038\/onc.2012.190 (2012).","journal-title":"Oncogene"},{"key":"46132_CR16","first-page":"5542","volume":"8","author":"M Luo","year":"2015","unstructured":"Luo, M., Shen, D., Wang, W. & Xian, J. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer. International Journal of Clinical and Experimental Pathology 8, 5542\u20135548 (2015).","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"46132_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep12460","volume":"5","author":"Z Xishan","year":"2015","unstructured":"Xishan, Z., Ziying, L., Jing, D. & Gang, L. MicroRNA-320a acts as a tumor suppressor by targeting BCR\/ABL oncogene in chronic myeloid leukemia. Scientific Reports 5, 12460, https:\/\/doi.org\/10.1038\/srep12460 (2015).","journal-title":"Scientific Reports"},{"key":"46132_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","volume":"76","author":"K Kotagama","year":"2015","unstructured":"Kotagama, K., Chang, Y. & Mangone, M. miRNAs as Biomarkers in Chronic Myelogenous Leukemia. Drug Development Research 76, 278\u2013285, https:\/\/doi.org\/10.1002\/ddr.21266 (2015).","journal-title":"Drug Development Research"},{"key":"46132_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/gcc.22334","volume":"55","author":"S Avigad","year":"2015","unstructured":"Avigad, S. et al. miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. Genes, Chromosomes and Cancer 55, 328\u2013339, https:\/\/doi.org\/10.1002\/gcc.22334 (2015).","journal-title":"Genes, Chromosomes and Cancer"},{"key":"46132_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872\u2013884, https:\/\/doi.org\/10.1182\/blood-2013-05-501569 (2013).","journal-title":"Blood"},{"key":"46132_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.brainres.2010.08.074","volume":"1359","author":"Y Nan","year":"2010","unstructured":"Nan, Y. et al. MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Research 1359, 14\u201321, https:\/\/doi.org\/10.1016\/j.brainres.2010.08.074 (2010).","journal-title":"Brain Research"},{"key":"46132_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/10245332.2016.1252020","volume":"22","author":"I Soltani","year":"2017","unstructured":"Soltani, I. et al. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. Hematology 22, 201\u2013207, https:\/\/doi.org\/10.1080\/10245332.2016.1252020 (2017).","journal-title":"Hematology"},{"key":"46132_CR23","first-page":"9154","volume":"8","author":"Z Su","year":"2015","unstructured":"Su, Z., Zhao, J., Rong, Z., Geng, W. & Wang, Z. MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancer. International Journal of Clinical and Experimental Pathology 8, 9154\u20139160 (2015).","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"46132_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.leukres.2011.03.029","volume":"35","author":"T Lopotov\u00e1","year":"2011","unstructured":"Lopotov\u00e1, T., \u017d\u00e1\u010dkov\u00e1, M., Klamov\u00e1, H. & Moravcov\u00e1, J. MicroRNA-451 in chronic myeloid leukemia: miR-451\u2013BCR-ABL regulatory loop? Leukemia Research 35, 974\u2013977, https:\/\/doi.org\/10.1016\/j.leukres.2011.03.029 (2011).","journal-title":"Leukemia Research"},{"key":"46132_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.leukres.2011.08.023","volume":"36","author":"V Scholl","year":"2012","unstructured":"Scholl, V., Hassan, R. & Zalcberg, I. R. miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. Leukemia Research 36, 119\u2013121, https:\/\/doi.org\/10.1016\/j.leukres.2011.08.023 (2012).","journal-title":"Leukemia Research"},{"key":"46132_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0025-2","author":"M Panagal","year":"2018","unstructured":"Panagal, M. et al. MicroRNA21 and the various types of myeloid leukemia. Cancer Gene Therapy. https:\/\/doi.org\/10.1038\/s41417-018-0025-2 (2018).","journal-title":"Cancer Gene Therapy"},{"key":"46132_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2014.02.008","volume":"53","author":"AF Ferreira","year":"2014","unstructured":"Ferreira, A. F. et al. ApoptomiRs expression modulated by BCR\u2013ABL is linked to CML progression and imatinib resistance. Blood Cells, Molecules, and Diseases 53, 47\u201355, https:\/\/doi.org\/10.1016\/j.bcmd.2014.02.008 (2014).","journal-title":"Blood Cells, Molecules, and Diseases"},{"key":"46132_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3978\/j.issn.2305-5839.2015.09.20","volume":"3","author":"J Chen","year":"2015","unstructured":"Chen, J., Xu, T. & Chen, C. The critical roles of miR-21 in anti-cancer effects of curcumin. Annals of Translational Medicine 3, 330, https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.09.20 (2015).","journal-title":"Annals of Translational Medicine"},{"key":"46132_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2016.03.043","volume":"387","author":"ML Abba","year":"2017","unstructured":"Abba, M. L. et al. MicroRNAs as novel targets and tools in cancer therapy. Cancer Letters 387, 84\u201394, https:\/\/doi.org\/10.1016\/j.canlet.2016.03.043 (2017).","journal-title":"Cancer Letters"},{"key":"46132_CR30","doi-asserted-by":"publisher","first-page":"21918","DOI":"10.18632\/oncotarget.4204","volume":"6","author":"S Taverna","year":"2015","unstructured":"Taverna, S. et al. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget 6, 21918\u201321933, https:\/\/doi.org\/10.18632\/oncotarget.4204 (2015).","journal-title":"Oncotarget"},{"key":"46132_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1349-7006.2010.01489.x","volume":"101","author":"Y Li","year":"2010","unstructured":"Li, Y. et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Science 101, 948\u2013954, https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01489.x (2010).","journal-title":"Cancer Science"},{"key":"46132_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbrc.2014.10.107","volume":"454","author":"W-Z Wang","year":"2014","unstructured":"Wang, W.-Z. et al. Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN. Biochemical and Biophysical Research Communications 454, 423\u2013428, https:\/\/doi.org\/10.1016\/j.bbrc.2014.10.107 (2014).","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"46132_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/10245332.2017.1292204","volume":"22","author":"HA Labib","year":"2017","unstructured":"Labib, H. A., Elantouny, N. G., Ibrahim, N. F. & Alnagar, A. A. Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. Hematology 22, 392\u2013397, https:\/\/doi.org\/10.1080\/10245332.2017.1292204 (2017).","journal-title":"Hematology"},{"key":"46132_CR34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal, J. E. et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63, 789 (1984).","journal-title":"Blood"},{"key":"46132_CR35","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford, J. et al. A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon AlfaWriting Committee for the Collaborative CML Prognostic Factors Project Group. JNCI: Journal of the National Cancer Institute 90, 850\u2013859, https:\/\/doi.org\/10.1093\/jnci\/90.11.850 (1998).","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"46132_CR36","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford, J. et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118, 686, https:\/\/doi.org\/10.1182\/blood-2010-12-319038 (2011).","journal-title":"Blood"},{"key":"46132_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann, M. et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30, 48\u201356, https:\/\/doi.org\/10.1038\/leu.2015.261 (2016).","journal-title":"Leukemia"},{"key":"46132_CR38","doi-asserted-by":"publisher","first-page":"e2540","DOI":"10.1038\/cddis.2016.461","volume":"8","author":"F Jin","year":"2017","unstructured":"Jin, F. et al. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death & Disease 8, e2540, https:\/\/doi.org\/10.1038\/cddis.2016.461 (2017).","journal-title":"Cell Death & Disease"},{"key":"46132_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-7","volume":"13","author":"J Li","year":"2013","unstructured":"Li, J. et al. MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell International 13, 7, https:\/\/doi.org\/10.1186\/1475-2867-13-7 (2013).","journal-title":"Cancer Cell International"},{"key":"46132_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","volume":"39","author":"R Alves","year":"2015","unstructured":"Alves, R. et al. Drug transporters play a key role in the complex process of Imatinib resistance in vitro. Leukemia Research 39, 355\u2013360, https:\/\/doi.org\/10.1016\/j.leukres.2014.12.008 (2015).","journal-title":"Leukemia Research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46132-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:06:43Z","timestamp":1671275203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46132-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46132"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46132-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"11 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9666"}}